Vésale Bioscience Named Most Innovative Start-up in Life Sciences in Europe at Tenth Edition of BioFIT
Vésale Bioscience, a biotech company specializing in phage therapy, with a particular focus on research into alternative solutions to antibiotics and the development of treatments for multidrug-resistant infections, announces today that it has been awarded the prize for most innovative start-up in life sciences in Europe during the tenth edition of BioFIT, which was held digitally from December 7–9, 2021.
BioFIT is the leading event in Europe in technology transfer, academia-industry collaboration and early-stage innovations in the field of life sciences. It is also the European marketplace for investments in seed and risk capital in life sciences. This year, 92 early-stage projects made submissions across all categories. From these, the selection committee retained 47 projects, which all pitched in front of an expert jury. In their evaluation process, the members of the jury primarily considered the impact of the innovation being developed and the company’s capacity to implement the project.
This prize shows the importance of phage therapy and confirms the contribution Vésale Bioscience’s technology is making in the fight against antimicrobial resistance. The start-up has developed Inteliphage®, a phagogram using artificial intelligence that enables decentralized diagnostics and personalized treatment. The technology is highly responsive, providing results in three hours, an improvement on the current three-day period. The company holds a library of phages with over a hundred different references, enabling them to tailor the treatment to the patient. This technology, which can easily be reproduced in specialized centers, provides a practical solution to a global public health issue. Commercialization is set for 2023.
“We are very proud to receive this award. It recognizes the great work performed by the Vésale Bioscience team and further motivates us to pursue our research into solutions to multidrug-resistant infections, which constitute a major global public health challenge,” said Jehan Liénart, CEO and founder of Vésale Bioscience. “We are in the middle of a Series A funding round; this prize serves to validate our development choices and our credibility. It shows our future partners that they can trust our work and our phage therapy solution.”